Skip to main content
main-content

04-12-2018 | Lymphoma | Video

Two-year follow-up and high-risk subset analysis of ZUMA-1

Frederick Locke discusses long-term follow-up results from the ZUMA-1 trial, demonstrating high rates of durable response to axicabtagene ciloleucel treatment among patients with refractory large B-cell lymphoma (4:28).

Funding for this video was provided in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

image credits